Clinical Trial – Immune Response to Shingles Vaccination – Shingles

The purpose of this study is to learn more about the immune response to varicella zoster virus (VZV).

Participants 70 years of age or older will receive the FDA-approved shingles vaccine (Zostavax). Blood samples and optional skin biopsies will be obtained before and after vaccination to study the immune responses to shingles vaccination.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Immune Response to Shingles Vaccination
Study Start Date : February 2016
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018
Contacts
Contact: Study Coordinator Virology Research Clinic 206-520-4340 vrc@uw.edu

 

ClinicalTrials.gov Identifier: NCT02624375

For enrollment please visit www.clinicaltrials.gov.

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.